An Alnylam spokesperson said the company was evaluating its options and may appeal. A BioNTech spokesperson said the filing "confirms Pfizer's and BioNTech's position that we do not infringe any ...

Twenty-two years in and Alnylam Pharmaceuticals is still not raking in any profit. But that’s a testament to the company’s R&D focus, because it takes more than one or two successful drugs to ...

Alnylam Pharmaceuticals experienced an 8% price increase over the past week, likely spurred by a positive opinion from the European Medicines Agency (EMA) regarding its RNAi therapeutic ...

When Alnylam Pharmaceuticals founding CEO John Maraganore left the company in late 2021, he joked that he wanted to be a “grandfather” of biotech—not leading any companies, per se ...

Getty Images Alnylam Pharmaceuticals announced a Phase-3 study of its treatment for a rare heart condition showed a significant reduction in deaths and recurrent cardiovascular events. The ...

C5b subsequently exposes a binding site for C6 and C5bC6 reversibly binds to the cell surface ... targeting C5 and cemdisiran is a small interfering ribonucleic acid (siRNA) which interferes with mRNA ...

Alnylam Pharmaceuticals reports a 48% increase in net product revenue in Q1 2023, driven by the launch of Amvuttra and increased patients on Givlaari and Oxlumo therapies. The company's ...

Shares of Alnylam Pharmaceuticals Inc. soared 57.0% in premarket trading on Wednesday after the company said its investigational RNAi therapeutic for a type of heart failure met the primary ...

Alnylam has set out how it plans to deliver siRNA to the central nervous system and other tissues beyond the liver. Writing in Nature Biotechnology, the RNA specialist shared details of how the ...

Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the ...